You are here

nirsevimab

RSV is on the rise but preventative drugs are in short supply

MIT Technology Review

Mon, 11/6/23 - 10:04 am

FDA Approves Sanofi and AstraZeneca’s RSV Antibody for Newborns, Infants

BioSpace

Mon, 07/17/23 - 07:00 pm

5 FDA decisions to watch in the third quarter

BioPharma Dive

Mon, 06/26/23 - 10:04 am

SAGE Therapeutics

FDA starts review of Sanofi, AZ antibody for RSV prevention

Pharmaphorum

Thu, 01/5/23 - 10:20 am

Sanofi, AstraZeneca clinch first OK for RSV antibody — just as vaccines line up at regulators

Endpoints

Fri, 11/4/22 - 10:21 am

Sanofi, AZ's blockbuster hopeful RSV med nears first approval as showdown with Pfizer, GSK looms

Fierce Pharma

Fri, 09/16/22 - 10:54 am

AZ, Sanofi build case for one-shot RSV antibody

Pharmaforum

Wed, 05/11/22 - 10:31 am

Sanofi, AstraZeneca Express Optimism Over Phase III Infant RSV Results

BioSpace

Thu, 03/3/22 - 10:24 am

clinical trials

Sanofi, AstraZeneca mark big leap toward filing of RSV drug in 2022, with safety data in hand to challenge Synagis

Endpoints

Mon, 06/28/21 - 10:58 am

clinical trials

AstraZeneca and Sanofi Announce Big Breakthrough With RSV Vaccine

BioSpace

Mon, 04/26/21 - 10:41 am

clinical trials